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Mutations in the COL4AS gene in Alport syndrome: A possible
mutation in primordial germ cells. Using a combination of gene amplifi-
cation with single strand conformation polymorphisms analysis and se-
quencing, we examined the COL4A5 gene in 37 patients with Alport
syndrome. In patient A8, a single base insertion was noted at codon 1,597
tyrosine in exon 49. The premature terminal signal appeared and 89 amino
acids (approximately one-third) of the non-collagenous domain were lost.
The mutation was present in the mother, hence she is heterozygous, In
patient A12, the nucleotide changed from C to Tat codon 1,679 glutamine
in exon 51, which created a termination codon, and 7 amino acids at the
carboxyl terminus were lost. Gene tracking using peripheral leukocytes
revealed that the parents did not carry the mutant allele, while the sister
was heterozygous. DNA samples from hair roots and skin fibroblasts of the
mother were normal and immunological examination of the epidermis of
the mother indicated that the a5(IV) chain was normally expressed. As
these results suggest that somatic cells of the mother do not carry the
mutant allele, the primordial germ cells possibly carry a fresh mutation in
the mother of patient A12.
Alport syndrome [1] is an inherited progressive kidney disease.
The disease, which characteristically leads to end-stage renal
disease in affected males, is initially characterized by hematuria,
and frequently also high-tone sensorineural deafness and eye
lesions. Carrier females have a variable and generally milder
clinical course [2]. Electron microscopy (EM) shows diffuse
irregularly thickening and splitting of the lamina densa in the
glomerular basement membrane (GBM). Ultrastructural findings
and immunological evidence suggest that the principal defect in
the disease is due to a complete absence of, or alterations in an a
chain of type IV collagen, a major structural component of the
GBM [3—6]. The COL4AS gene mapped to Xq22 encodes the a5
chain of the type IV collagen [7, 8]. Full-length cDNA clones
providing the complete amino acid sequence of the a5(IV)
collagen have been isolated and characterized [9]. Major rear-
rangements such as large deletions [10—14] and duplication [11],
single base mutations [9, 12, 15—18] including splicing mutations
[19, 20], and single base insertion [21] in the region of the
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COL4AS gene have been noted in patients with X-linked Alport
syndrome.
To initiate a search for minor mutations such as one point
mutation, single base insertion or deletion in the COL4A5 gene,
we carried out a combination of amplification of the exons coding
for the non-collagenous (NC1) domain with single strand confor-
mation polymorphisms (SSCP) [22] and sequencing of the ampli-
fied DNA fragments. In 37 unrelated Japanese patients with
Alport syndrome, we identified two patients with a novel mutation
in the 3' end of the gene; one was a single base (A) insertion,
resulting in a stop codon (TAA), and the other was a single base
substitution with a nonsense mutation that was inherited from the
mother. The mutation in primordial germ cells of the mother was
speculated in the latter case.
Methods
Materials
To amplify exons 47-5 1 encoding the NC1 domain in the type
IV collagen a5 chain, six pairs of oligonucleotide primers were
synthesized, based on the sequence of the COL4A5 gene [23] and
the flanking sequence of exon 48 (primers IVA and IVB) that we
have isolated and characterized [21]. The sequences of oligonu-













Genomic DNAs were extracted from peripheral leukocytes
from 37 unrelated Japanese individuals with Alport syndrome,
according to the standard method [24]. Genomic DNA was
amplified in vitro by polymerase chain reaction (PCR) [25, 26].
PCR conditions were as described elsewhere [21]. For SSCP
analysis, the amplified DNA was denatured at 94°C for three
minutes and electrophoresed under non-denaturing conditions on
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Fig. 1. PCR-SSCP-silver staining analysis.
Amplified DNAs were denatured at 94°C for
3 minutes and electrophoresed on 7.5%
polyacrylamide gels with 6% glycerol at 4°C at
100 volts for 10 hours. The DNA was
detected after silver staining. SSCP in exon 49
(A) and exon 51(B). C, normal male control;
A8, patient A8; A12, patient A12. Compared
to control samples, the mobilities of the
amplified DNAs of the patients were clearly
altered, as indicated by arrowheads.
7.5% polyacrylamide gels with or without 6% glycerol at 4°C at
100 volts for 10 hours. The DNA was detected after silver staining
[27]. The amplified DNA was subcloned into the pUC18 vector,
and sequenced by the dideoxy chain termination method [28]
using 7-DEAZA Sequencing kit Ver. 2.0 (USB). For gene track-
ing, amplified DNAs from patients and their families were
digested with restriction enzyme MseI (T/TAA), then electropho-
resed on 4% NuSieve GTG agarose gels.
To determine whether somatic mosaicism was present in the
mother of patient A12, DNAs extracted from her hair roots and
skin fibroblasts were amplified and digested with restriction
enzyme MseI. Ten hair roots pulled out ubiquitously were sus-
pended in distilled water and boiled at 94°C at 10 minutes. Nested
PCR was done using the same reaction tube. The first PCR was
carried out with primers 50A and lB (5'-TTCTTGGAGAAAGT-
CATTCTGGAC-3', 3'-flanking sequence of the COL4A5 gene
[231). Using a sample (5 .d) of the product as a template, the
second PCR was done with primers 51A and 51B. Skin fibroblasts
were cultured in RPMI 1640 supplemented with 10% fetal calf
serum, glutamine and penicillin/streptomycin in standard concen-
trations, and DNA was extracted. PCR was carried out with
primers 51A and SiB. Amplified DNAs were digested with MseI
and electrophoresed as described above.
A peptide corresponding to the non-consensus amino acid
residues 1652-1664 (VDVSDMFSKPQSE) of the NC1 domain of
a5(IV) chain [7] was synthesized. The synthetic peptide was
conjugated with a carrier protein and a rat was immunized. A
monoclonal antibody (H51, rat IgG2a, K-chain) was established
and it bound to peptides corresponding to the VDVSDMFSKP
region of the có(IV) NC1 peptide [29]. Indirect immunofluores-
cence study of the a5(IV) chain of epidermal basement mem-
brane (EBM) was carried out for the mother of patient A12. Snap
frozen specimens of the epidermis were cut into the 2 rm-thick
sections and fixed with acetone for ten minutes then denatured
with the 6 M urea glycine HC1, pH 3.2. These preparations were
incubated at 4°C overnight with the rat monoclonal antibody H51.
They were further incubated with fluorescein-isothiocyanate
(FITC) labeled goat anti-rat IgG (Capell Instruments Corp.) at
37°C for one hour, followed by Nikon fluorescence microscopy.
Patients
Patient A8 is a 12-year-old boy with Alport syndrome and
sensorineural deafness. Gross hematuria occurred when he was 14
months old and proteinuria was evident when he was four years
old. EM examination of glomeruli obtained at renal biopsy at the
latter age revealed that the lamina densa of GBM had widened
and split into several layers (data not shown), findings compatible
with a diagnosis of Alport syndrome. Massive proteinuria (3 to 5
day) and hypoalbuminemia (serum albumin, 2.3 g/dl) occurred
when he was 11 years old. Proteinuria (1 to 2 glday) and
hematuria (2+ by dipstick) persist at present. Serum creatinine is
1.5 mgldl. Bilateral high tone sensorineural deafness was evident
at age four years, but the eyes remained intact. The mother and
the maternal aunt have hematuria only.
Patient A12 is a 15-year-old boy with Alport syndrome without
sensorineural deafness. Hematuria and proteinuria were detected
when he was five years old. EM examination of glomeruli showed
findings similar to those of patient A8 (data not shown). At
present, he has hematuria (3+) and proteinuria (± to 2+) by
dipstick, and serum creatinine is 0.8 mg/dl. High tone sensorineu-
ral deafness and eye lesions are absent. The parents have a normal
urinalysis. He has a seven-year-old sister with hematuria (3+) and
proteinuria (±) by dipstick, as detected at age four years. Renal
dysfunction, ear and eye lesions are absent in the sister. Patient
A12 proved to be the son of the parents, as determined by DNA
fingerprints using single locus probes CMM1O1 and YNH24 (data
not shown).
Results
We screened exons 47-5 1 coding for the NC1 domain for minor
mutations using PCR-SSCP analysis. As shown in Figure 1, the
mobilities of the amplified DNAs of two patients (A8 and A12)
were clearly different from those of control samples with regard to
exon 49 and exon 51, respectively.
In patient A8, DNA sequencing of amplified products revealed
a single base (A) insertion between nucleotides A-4,993 and
T-4,994 at codon 1,597 tyrosine [9] in exon 49 (Fig. 2A). To
exclude PCR errors, the result was confirmed by sequencing the
products generated by ten other independent amplifications. This
mutation led to a change from the tyrosine codon to the stop
codon, TAA (Fig. 3A). The mutation resulted in synthesis of the
truncated a5(IV) collagen chain that lacked 89 amino acids
(approximately one-third) of the NC1 domain (Fig. 3A). As the
mutation generated a new MseI site (restriction site, T/TAA) in
the region of exon 49, digestion with MseI of the amplified DNAs
was used for gene tracking. There was no MseI site in the
amplified product (175 bp) of exon 49 from the normal control
(Fig. 4). When the amplified DNA from the patient was digested
with MseI, a 175 bp fragment was absent and new fragments (130
and 46 bp) appeared (Fig. 4). The sample from the mother of
patient A8 contained fragments of 175 bp, 130 bp and 46 bp by
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Fig. 2. Sequencing of PCR amplified DNAs.
Partial nucleotide sequences of amplified
DNAs with primers 49A and 49B (A), and
primers 51A and SiB (B). Left, normal male
control; right, patients AS (A) and A12 (B).
A. The mutation in patient AS proved to be a
single base insertion (indicated by
arrowheads) between nucleotides A-4993 and
T-4994 [11]. B. In patient A12, nucleotide
5,238 was changed from C to T indicated by
arrowheads.
type and mutant alleles. DNA samples from other members of the
family could not be obtained.
In patient A12, nucleotide 5,238 was changed from C to T,
converting codon 1,679 glutamine in exon 51 to stop codon, TALk
(Figs. 2B, 3B). The result was confirmed by the procedure
described above. This mutation resulted in synthesis of a trun-
cated protein lacking seven amino acid residues at the earboxyl
terminus (Fig. 3B). The amplified product (192 bp) in exon 51
from the normal control was digested with MseI, producing two
fragments (138 and 54 bp) (Fig. 5). In the patient, a fragment of
138 bp was absent and two new fragments (88 and 50 bp), in
addition to an original 54 bp fragment, were observed, because an
additional MseI site had formed with the mutation in exon 51 (Fig.
5). The sample from the sister of the patient contained fragments
of 138 bp, 88 bp, 54 bp and 50 bp, indicating that she was
heterozygous with the mutant and the wild type alleles. The father
and the mother carried only the wild type alleles.
We investigated additional DNA samples obtained from hair
roots and cultured skin fibroblasts from the mother of patient
A12. MseI digestion revealed that amplified DNAs from hair roots
and fibroblasts showed the normal fragment (138 bp) only (Fig. 6).
These results suggest that the mother of patient A12 is not
heterozygous, at least with regard to peripheral leukocytes, hair
roots and cultured skin fibroblasts. Immunofluoreseence study
with the anti-aS(IV) antiserum gave linear stainings for the
epidermal basement membrane of the mother, findings similar to
that of a normal male control (Fig. 7).
Discussion
We examined the 3'-end of the COMAS gene in 37 Japanese
patients with Alport syndrome, using PCR-SSCP-silver staining
analysis, and we identified five mutations; one patient with a single
base insertion [21], two with a splicing mutation (in preparation),
and two patients in this study. The mutations heretofore reported
[9—20] differed from those found in our patients and were
ubiquitously in the COMM gene from triple-helical to NC1
domains. The detection rate of mutations by our methods, which
was limited to identification of mutations located at the NC1
domain, was 13% (5 of 37). In the remaining 32 patients, no
abnormal bands were detected in five exons 47-5 1 covering the
Amino acid 1597
C W D S L W I G Y S
Normal GGA TCC CAT TCT CTC TGG APr GGT TAT TCC
1'
I,
Patient A12 CGA TGT TAA GTG TGC ATG AAG AGG ACA TAA
Patient A8 GGA TGG CAT TCT CTG TGG AlT GGT TAA TFCG W D S L W I C *
4 Helical '4 Nd domain
Amino acid 1679 1685
It C Q V £ M K R T *
Normal CCATGTCAAGTGTGC ATC AAG AGG ACA TAA
iØ— Helical NC1 domain
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Fig. 3. The amino acid sequence and deduced
protein of the a5(Ik9 collagen chain of patients.
Top. Amino acid numbers start at the
translation initiator methionine [11].
Nucleotide and deduced amino acid
sequences in normal control and patients are
shown by inner and outer lines, respectively.
The mutations are indicated by arrowheads,
and stop codons by asterisks. Bottom.
Illustration of deduced protein of the a5(IV)
collagen chain of patients. A. A single base
insertion in patient A8 led to change from
1597 tyrosine codon into stop codon, TAA.
The deduced protein would lack about one-
third of the NC1 domain shown by the gray
box. B. A single base mutation in patient A12
led to a change from 1679 glutamine codon
into stop codon, TAA. The deduced protein
would lack 7 amino acids (1679.1685) at its
carboxyl terminus shown by the gray box.
NC1 domain. They may have a mutation in other exons of the
COL4A5 gene encoding the triple helical domain, or the COL4A6
gene mapped to Xq22 encoding the newly found a6(IV) chain
[30]. Further studies on the remaining regions are needed.
In patient A8, the mutation in exon 49 resulted in the absence
of approximately one-third of the NC1 domain of a5(IV) chain.
We found a single base insertion in exon 48 in another patient
(OYM) [21]. Both mutations created a terminal codon and both
patients had similar clinical findings of the X-linked juvenile form
of Alport syndrome with high-tone sensorineural deafness,
though the extent of the absence of the NC1 domain in patient
OYM was greater than that in patient A8 (2/3 vs. 1/3) [21]. In patient
A12, seven amino acid residues 1,679 to 1,685 (QVCMKRT) at
the carboxyl terminus were absent, as a result of a nonsense
mutation.
The NC1 domain seems to be crucial for the correct alignment
of three a chains prior to their folding into the triple-helical
conformation in a manner similar to that in type I collagen [31];
it is essential for the head-to-head cross-linking between the
carboxyl terminals of two triple-helical molecules during forma-
tion of the type IV collagen network [32, 33]. These functions
require the correct conformation of the NC1 domain that is
maintained by disulfide bonds. The truncated NC1 domain found
in patient A8 would mean that the structure of type IV collagen
would not develop normally. In patient A12, the lack of the last
cysteine residue of the NC1 domain, which contains 12 cysteine















Fig. 4. Pedigree of patient A8 and gene tracking by restriction enzyme MseI
digestion of amplified DNA. A. Pedigree of patient A8. Obligate female
carrier is shown as an open circle with a dot. Unaffected male and affected
male are shown as an open box and a closed box, respectively. The patient
is indicated by an arrowhead. B. Region of amplified DNA with primers
49A and 49B. The mutation is indicated by an asterisk. MseI restriction
site is indicated by a vertical line. C. Digestion of amplified DNA with
MseI and electrophoresis on a 4% NuSieve gel. C, normal male control; 12,
mother; Hi, patient; M, 1kb ladder marker. The patient is missing the 175
bp fragment and has the variant 130 bp and 46 bp fragments. His mother






Fig. 5. Pedigree ofpatientAl2 and gene tracking by restriction enzyme MseI
digestion of amplified DNA. A. Pedigree of patient A12. Unaffected female
is shown as an open circle. See Fig. 4A. B. Region of amplified DNA with
primers 51A and 51B. See Fig. 4B. C. Digestion of amplified DNA with
MseI and electrophoresis on a 4% NuSieve gel. Ii, father; 12, mother; 111,
patient; 112, sister; C, normal male control; M, 1kb ladder marker. The
patient is missing the 138 bp fragment and has variant fragments of 88 bp
and 50 bp. The sister is heterozygous with the normal and the variant
fragments. The father and the mother have only a normal fragment.
residues, would abolish one of the intra-chain or inter-chain
disulfide bonds. Accordingly, although protein examination was
not done, it is likely that mutations are causative for the disease.
Concerning the heredity of the disease in the patient A8 family,
the mutation was inherited from the maternal side. In the family
of patient A12, the parents are healthy with no urine abnormality,
yet the patient and his sister have had hematuria and proteinuria.













carried only wild type alleles. Thus, further detailed studies on the
mother are needed, since the disease is inherited in an X-linked
fashion. First, we examined paternity and maternity of the chil-
dren, using DNA fingerprints. We also did a gene analysis of
somatic cells of the mother in addition to peripheral leukocytes,
since carriers of Lesch-Nyhan syndrome with X-linked inherited
disease often have the wild type allele alone in peripheral
leukocytes [34]. MseI digestion showed that both hair roots
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Fig. 6. MseI digestion of amplified DNAs from hair roots and cultured skin fibroblasts of patient A12's mother. Ten hair roots pulled out ubiquitously were
suspended in distilled water and boiled at 94°C at 10 minutes. Nested PCR was done. First PCR was carried out with primers 50A and lB. Using the
product as a template, a second PCR was done with primers 51A and 51B. The DNA extracted from cultured skin flbroblasts was amplified with primers
51A and 51B. Amplified DNAs were digested with restriction enzyme MseI (lanes 2, 4 and 6) or without the enzyme (lanes 1, 3 and 5), and
electrophoresed on a 4% NuSieve gel. Leukocytes in a normal male control (lanes 1 and 2), hair roots (lanes 3 and 4) and cultured skin flbroblasts (lanes
5 and 6) in the mother of patient A12; M, 1kb ladder marker. A fragment of 54 bp ran off the gel. The mother had the normal fragment (138 bp) in
hair roots and skin flbroblasts but not the variant one (88 bp).
Fig. 7. Indirect immunofluorescence study of epidermal basement membrane (EBM) with anti-o5(IV) antibody H51 in the patient A12's mother and a
normal male control. The 2 inn-thick cryosections were incubated at 4°C overnight with the rat monoclonal antibody against the peptide of NC1 domain
of a5(IV) chain. The sections coated with primary antibody were incubated with FITC-labeled goat anti-rat IgG at 37°C for one hour, followed by Nikon
fluorescence microscopy. The EBMs are indicated by arrowheads. A. patient A12's mother, (X400). B. normal male control, (X354). The EBMs of
patient A12's mother and a normal male control are strongly stained by anti-a5(IV) antibodies.
(ectoderm) and skin fibroblasts (mesoderm) from the mother
carried the wild type allele of the COL4A5 gene alone. An
indirect immunofluorescence pattern of EBM was similar to that
seen in normal controls. In male patients with Alport syndrome,
neither GBM nor EBM reacted with H51 [291. In heterozygous
females; there was a discontinuous or mosaic pattern in the
immunofluorescent staining of the GBM and EBM with FNS1
[35] and H51 [29]. Based on these findings, the mother does not
seem to be a heterozygous female with Alport syndrome. A
similar situation was noted in Duchenne muscular dystrophy,
another X-linked inherited disease [36, 37]. Bakker et al described
two families in which deletion of the dystrophin gene was trans-
mitted to more than one offspring by women with no evidence for
the mutation in their own somatic (white blood) cells [361. Darras
and Francke reported that deletion of the dystrophin gene was
present in two of five daughters of a woman who herself did not
have the mutation, and restriction fragment length polymorphism
markers indicated that the mutation was transmitted from the
unaffected father [37]. A most plausible explanation is that the
mutation must have occurred during mitosis in early germ-line
proliferation. The studies presented here showed that the muta-
tion in family A12 occurred at some stage after dividing primor-
dial germ cells from somatic cells during the embryonic develop-
ment of the mother, since she carried the wild type allele alone at
least in three somatic tissues and if studies on the epidermis
revealed normal findings. If the mutation occurred early in
embryogenesis, the primordial germ cells would be a homologous
mutation, while if later, they would be mosaicism. The recurrence
risk would be related to the extent of the subsequent germ-line
mosaicism. Murray, Giles and Lillicrap reported that in a family
with type JIB von Willebrand disease, analysis of the sperm from
a phenotypically normal grandfather showed that approximately
5% of the germ-line contained the mutant sequence [38]. In the
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obtained from the mother. Ovary or ovum examinations may be
revealing. It is possible that a fresh mutation of the COL4A5gene
in primordial germ cells (homologous mutation or mosaicism) in
the mother results in the hemizygote (patient A12) and the
heterozygote (a sister of the patient) of Alport syndrome. The
mutation will be passed down to their offspring.
In subjects with Alport syndrome, familiar gene tracking was
carried out in 17 families, including present cases, and de novo
mutation was found three families (3 of 17, 17%) [14, 18]. The
figure is close to that reported (18%) by Shaw and Kallen [39].
We conclude that gene analysis including familiar gene tracking
is important, in addition to pathophysiological studies of the
propositus.
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